kaal:position:2026-07-31-5633

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential should be assessed against Kaal's source-bound claim that When disruptive firms do not comply with existing rules or write their own exemptions because no appropriate rules exist, consumer protection and public safety goals are undermined and incumbent firms still bound by the rules suffer severe competitive disadvantages. The current metadata indicates a plausible connection through model context protocol, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

disruptive products or services that fall outside or evade the existing regulatory framework
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Scholarly basis

kaal:claim:2740477-009
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2012
Mapping ambiguous: true

Topics

regulatory-failureinnovation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0023 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 22df259635c7866428c4ae5a31cead5d07fb5c3a238a4a41660b4f230710c3aa
curl -s https://wulfkaal.github.io/positions/2026-07-31-5633.md | sha256sum